IL-11对造血的刺激作用及其在辐射损伤治疗中的应用

王欣茹 ,  郝静 ,  罗庆良

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2003,  27 > 1: (42-44)  
引用本文:
shu
Citation:
shu

IL-11对造血的刺激作用及其在辐射损伤治疗中的应用

  • 100850 北京, 军事医学科学院放射医学研究所

    • 作者简介: 王欣茹(1968-),女,实验师,硕士研究生,主要从事急性放射病治疗研究。;郝静(1974-),女,助理研究员,硕士,主要从事急性放射病治疗研究。;罗庆良(1952-),男,研究员。;

  • 中图分类号: Q5-33;R818.05

Stimulation effects of recombinant human interleukin-11 on heamatopiesis and the application in the treatment of acute radiation injury

  • Institute of radiation medicine, Academy of military medicalsciences, Beijing 100850, China

  • CLC number: Q5-33;R818.05

  • 摘要: 体内外实验结果表明,IL-11(白细胞介素-11)可刺激骨髓巨核系、粒系和红系造血祖细胞的增殖,升高外周血小板、白细胞和红细胞数。因此,IL-11作为一种新的刺激骨髓造血细胞增殖的细胞因子具有它的特殊价值,可用于平时辐射事故病人和核战时伤员的救治,也可用于癌症患者放、化疗后造血功能低下的治疗,具有广阔的临床应用前景。
    Abstract: In the present experiment, recombinant human interleukin-11 (rhIL-11) significantly improved the proliferation activity of hematopoietic cells in the human bone marrow cell culture and increased the number of colonies of multilineage progenitor cells. Meylosuppressed mice or rhesus monkeys by chemo-or radiotherapy had higher platelet counts than those of controls after rhIL-11 treatment. rhIL-11 is safe and effective in reducing chemo-and/or radiotherapy associated thrombocytopenia and the need for platelet transfusions in patients who undergo intensive chemotherapy. rhIL-11 is likely to become an effective agent in correcting meylosuppression induced by radiation or chemotherapy
  • [1] Lazzari L, Lucchi S, Rebulla P, et al. Long-term expansion and maintenance of cord blood haematopoietic stem cells using thrombopoietin, Flt3-ligand, interleukin(IL)-6 and IL-11 in a serum-free and stroma-free culture system[J].Hema-tology, 2001, 112:397-404.
    [2] Taguchi K, Saitoh M, Arai Y, et al. Disparate effects of interleukin 11 and thrombopoietin on megakaryocytopoiesis in vitro[J]. Cytokine, 2001,5:241-249.
    [3] Weich NS, Fitzgerald M, Wang A, et al. Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro[J]. Blood, 2000, 95:503-509.
    [4] Cairo MS, Plunkett JM, Nguyen A, et al. Effect of interleukin-11 with and without granulocyte colony-stimulating factor on in vivo neonatal rat hematopoiesis:induction of neonatal thrombocytosis by interleukin-11 and synergistic enhancement of neutrophilia by interleukin-11+granulocyte colony-stimulating factor[J]. Pediatr Res, 1993, 34:56-61.
    [5] Nash RA, Seidel K, Storb R, et al. Effects of rhIL-11 on normal dogs and after sublethal radiation[J]. Exp Hematol,1995, 23:389-396.
    [6] Schlerman FJ, Bree AG, Kaviani MD, et al. Thrombopoietic activity of recombinant human interleukin 11(rHuIL-11) in normal and myelosuppressed nonhuman primates[J]. Stem Cells, 1996,14:517-532.
    [7] Saitoh M, Taguchi K, Momose K, et al. Recombinant human interleukin-11 improved carboplatin-induced thrombocy-topenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells[J]. Cancer Chemother Pharmacol, 2002, 49:161-166.
    [8] Saitoh M, Taguchi K, Momose K, et al. Kinetic analysis of megakaryopoiesis induced by recombinant human interleukin 11 in myelosuppressed mice[J]. Cytokine, 2001, 13:287-294.
    [9] Van der Meeren A, Mouthon MA, Gaugler MH, et al. Administration of recombinant human IL-11 after supralethal radiation exposure promotes survival in mice:interactive effect with thrombopoietin[J]. Radiat Res, 2002, 157:642-649.
    [10] Reynolds CH. Clinical efficacy of rhIL-11[J]. Oncology (Huntingt), 2000, 14(Suppl 8):32-40.
    [11] Issacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin[J]. J Clin Oncol, 1997, 15:3368-3377.
    [12] Feinglass S, Deodhar A. Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11[J]. Arthritis Rheum, 2001, 44:170-175.
    [13] Goldman SC, Bracho F, Davenport V, et al. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients[J]. Pediatr Hematol Oncol, 2001, 23:300-305.
    [14] Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP[J]. Hematol, 2001, 66:172-177.
    [15] Smith JW 2nd. Tolerability and side-effect profile of rhIL-11[J]. Oncology(Huntingt), 2000, 14(Suppl 8):41-47.
  • [1] 罗成基 . 白细胞介素-3与辐射损伤. 国际放射医学核医学杂志, 1995, 19(6): 263-266.
    [2] 李雨 , 蔡建明 , 刘及 . 白细胞介素I对造血干细胞的辐射防护作用. 国际放射医学核医学杂志, 1995, 19(4): 191-191.
    [3] 吴莹 , 孙金锴 , 李志旺 . 白细胞介素-1和肿瘤坏死因子的辐射防护作用. 国际放射医学核医学杂志, 1996, 20(6): 268-270.
    [4] 苗莉 , 缪竞诚 . 细胞因子在急性辐射损伤治疗中的作用. 国际放射医学核医学杂志, 2006, 30(3): 173-176.
    [5] 邢爽 , 李明 , 黄海潇 , 罗庆良 . 急性辐射损伤的细胞因子联合治疗研究进展. 国际放射医学核医学杂志, 2008, 32(1): 47-50.
    [6] 周华云 , 王国权 , 周剑影 , 罗成基 . 白细胞介素-6用于辐射损伤的治疗. 国际放射医学核医学杂志, 1996, 20(6): 265-267.
    [7] 刘志平 , 宋小英 . 细胞活素(白细胞介素-1,肿瘤坏死因子和转化生长因子β)在自然和脂多糖增强辐射抗性中的作用. 国际放射医学核医学杂志, 1992, 16(4): 168-168.
    [8] 田生礼 , 李健超 , 刘及 . 电离辐射对免疫活性细胞及白细胞介素产生的影响. 国际放射医学核医学杂志, 1990, 14(4): 148-151.
    [9] 孙元明 , 李雨民 . 注入白细胞介素Ⅰ鼠的辐射防护作用——与脾集落形成单位的关系. 国际放射医学核医学杂志, 1990, 14(1): 26-26.
    [10] 闵锐 . 辐射损伤防护药及细胞因子治疗研究动态. 国际放射医学核医学杂志, 2004, 28(4): 173-178.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  979
  • HTML全文浏览量:  72
  • PDF下载量:  4
出版历程
  • 收稿日期:  2002-09-27

IL-11对造血的刺激作用及其在辐射损伤治疗中的应用

    作者简介:王欣茹(1968-),女,实验师,硕士研究生,主要从事急性放射病治疗研究。;郝静(1974-),女,助理研究员,硕士,主要从事急性放射病治疗研究。;罗庆良(1952-),男,研究员。
  • 100850 北京, 军事医学科学院放射医学研究所
  • 收稿日期: 2002-09-27

摘要: 体内外实验结果表明,IL-11(白细胞介素-11)可刺激骨髓巨核系、粒系和红系造血祖细胞的增殖,升高外周血小板、白细胞和红细胞数。因此,IL-11作为一种新的刺激骨髓造血细胞增殖的细胞因子具有它的特殊价值,可用于平时辐射事故病人和核战时伤员的救治,也可用于癌症患者放、化疗后造血功能低下的治疗,具有广阔的临床应用前景。

English Abstract

    全文HTML

参考文献 (15)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net